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A B S T R A C T
Finding a better first antiretroviral regimen is one of the strategies used to improve span and 
quality of life of HIV/AIDS patients. 891 patients were followed during 24 months or until 
interruption/abandonment of treatment, changing regimen or death. At the end of 6 months, 
69% of the patients were still being treated with the first regimen, 54% at 12 months, 48% at 18 
months and 39% at 24 months. AZT-3TC-EFV was the most prescribed regimen and with the 
lesser discontinuation. NNRTI regimens showed high effectiveness and durability compared to 
PI regimens. Irregular medication dispensation was the only risk factor for failure/interruption 
of treatment in multivariate analyses. Intolerance/adverse effects were mainly responsible for 
first regimen discontinuation, followed by abandonment/non-adherence and virologic failure. 
Results showed significant difference between causes of interruption of first HAART with 
higher percentage of intolerance/adverse effects with PI regimens and higher immunologic 
failure with NNRTI regimens. Even with the availability of more potent and tolerable drugs, lack 
of adherence to HAART and high level of adverse effects are still the most important barriers 
to prolonged success of treatment. This study adds relevant information about durability and 
effectiveness of HAART in the first decade of its use in Brazil.
Introduction
The widespread use of highly active antiretroviral therapy 
(HAART) has led to major reductions in morbidity and 
mortality associated with HIV infection.1-4 The choice of initial 
HAART therapy has potential implications not only for short-
term success of therapy but also for long-term durability of 
antiretroviral activity, for immune system restoration and for 
adherence to the regimen, as well as to potential emergence 
of drug resistance.5 Effectiveness of first regimen is a 
debated topic in the world and several questions on the 
subject need more consistent answers. In Brazil, since 1996 
access to antiretroviral (ARV) therapy has been universal and 
free of charge to all individuals who qualify for treatment 
according to national guidelines. Nonetheless, despite the well 
recognized public health impact of the Brazilian AIDS program, 
there are important issues to be addressed regarding durability 
and determinants of HAART discontinuation. In the present 
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study, we assessed durability and determinants of initial 
HAART regimens discontinuation in a cohort of treatment-
naive patients who started ARVs between 1996 and 2005 in a 
referral center for infectious and parasitic diseases (CTR/DIP 
Orestes Diniz) in Belo Horizonte, Brazil.
Material and methods
Study population included all treatment-naive HIV-infected 
adults aged 18 or more on follow-up at CTR/DIP Orestes Diniz, 
for whom HAART had been prescribed between 1996 and 2005. 
Pregnant women were excluded from this analysis. The main 
objective was to ascertain the duration of the first HAART 
regimen in patients with HIV/AIDS. Secondary objectives were: 
to describe the main regimens prescribed and the temporal 
evolution; to identify possible risk factors associated with 
durability and effectiveness of the first antiretroviral regimen; 
and to identify the reasons for discontinuation or replacement 
of the first HAART regimen.
Data were abstracted from the medical records, from a 
database of laboratory tests and from antiretroviral inventory 
sheets at the local pharmacy. 
Data analysis included all patients who received their first 
antiretroviral combination containing at least three drugs 
throughout 24 months or until the suspension, abandonment 
or replacement of the regimen or death. Antiretroviral regimens 
were categorized in two major groups: protease inhibitor (PI) 
(regimens containing 2 nucleoside reverse transcriptase 
inhibitors [NRTIs] plus at least 1 PI, including ritonavir-
boosted regimens) and non-nucleoside reverse transcriptase 
inhibitor (NNRTI) (regimens containing 2 NRTIs plus 1 NNRTI). 
Demographic variables included gender, age, risk category, 
ethnicity, education level and marital status. 
The main endpoint was the time period for discontinuation 
of HAART, defined as the time at least one of the drugs in 
the regimen was stopped. Time-to-event was defined as the 
time from start of HAART to date to discontinuation. Regimen 
discontinuation or switch, date of occurrence and reason were 
documented. The reason for discontinuation was characterized 
as abandonment/non-adherence, pharmacological interaction, 
regimen inadequacy, therapeutic failure (virological, 
immunological or clinical), death or intolerance/adverse 
events. Only one category was considered as the reason for 
replacement or discontinuation. Virological failure was defined 
as viral load persisting above 400 copies/mL six months after 
beginning of HAART (primary virological failure) or viral RNA 
detection in at least two consecutive exams after having 
achieved complete viral suppression (secondary virological 
failure). Immunological failure was defined as reduction of 
more than 25% in the absolute number or in the percentage 
of T-CD4+ lymphocytes in at least two consecutive exams, 
in the absence of documented virological failure, according 
to Brazilian guidelines.6,7 Any AIDS-defining opportunistic 
infection (CDC/93) in patients with T-CD4+ lymphocyte nadir 
higher than 200 cells/mm3 was considered clinical failure.8 
In the absence of laboratory results, failure was deemed 
to be clinical. In other words, for virological failure of the 
regimen, the date of the viral load result was considered. For 
immunological failure, the date of the T-CD4+ count that led to 
HAART discontinuation was considered. In relation to clinical 
failure, the date of diagnosis of an opportunistic event was 
considered. 
When therapeutic failure was detected secondarily 
to abandonment/non-adherence to treatment, the latter 
was considered as the reason for discontinuation. When 
replacement was due to intolerance/adverse events, the 
suspected drug(s) and the type of adverse event(s) were 
identified. Other variables included reports of irregular use of 
medication in the medical records and irregular dispensing 
of medication; the latter based on the dispensing sheets of the 
CTR/DIP pharmacy and defined as dispensing less than 95% of 
the doses in the period. 
For patients who had not discontinued the initial 
combination, follow-up visits were discontinued after 24 
months (730 days) of therapy. 
Data were entered into the Epi-info 3.3.2 software and 
analyzed with the SPSS 13.0 (2004) software, initially in a 
descriptive manner. Type-I error of 5% was considered for 
comparison among groups. Survival curves were used to assess 
HAART duration and of the several antiretroviral regimens. 
Wilcoxon (Gehan) test was used for paired comparison among 
the most frequent regimens and comparison of treatment 
duration among drug classes. Chi-square test was used to 
evaluate: association between the level of T-CD4+ lymphocytes 
at the beginning of treatment and the class of the third drug 
in the regimen, reasons for discontinuation/failure for each 
drug class, and between gender and marital status and drug 
classes. In order to evaluate the relation between drug classes 
and education level, t test for independent samples was used. 
Mann-Whitney test was used for income and age and Cox 
proportional hazard model was to evaluate the relative risk of 
treatment discontinuation.
Ethics
The study was approved by the Ethical Committee of the 
Universidade Federal de Minas Gerais (COEP 569/07). 
Results
Among the 916 patients who fulfilled the eligibility criteria, 
25 (2.8%) were not included because the medical records were 
not found or the necessary information was missing. Thus, the 
study sample comprised 891 patients (Table 1). The majority 
of the patients were male (69.2%), single (52.1%), white (53.5%), 
from the city of Belo Horizonte (63.9%), with an average age 
of 36.3 years and education level of 8 years or less (65.8%). All 
patients had sexual risk for contracting the infection and 57.4% 
of men declared themselves as heterosexual. Most patients 
(548/62.5%) were on a regimen that included a PI. The groups 
had a similar socio-demographic profile. Regarding CDC/93 
classification, it was observed that, at the beginning of HAART, 
66.6% (578/859) had T-CD4+ lymphocytes count below 200 
cells/mm3 (categories A3, B3 and C3) and 31% (266/859) had 
an AIDS-defining condition (categories C1, C2 and C3), with 
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26% (221/859) presenting both an AIDS-defining condition and 
T-CD4+ lymphocyte count below 200 cells/mm3 (category C3). 
T-CD4+ lymphocyte count at the beginning of therapy was 
lower among those who started with a regimen containing a 
PI, as shown in Table 1.
Thirty-seven different combinations were prescribed as first 
combined antiretroviral regimen and 75% of the prescriptions 
comprised the eight more frequent combinations. The 
combination azidothymidine + lamivudine + efavirenz (AZT 
+ 3TC + EFV) was the most commonly prescribed, accounting 
for 21.3% of the regimens.
Between 1999 and 2001 there was a significant decrease 
in ritonavir use as the sole PI, as opposed to an increase of 
other regimens, especially the combination of AZT, 3TC 
and EFV. During the study period there was also a decrease 
in the prescription of regimens containing a PI as first line 
antiretroviral regimen (Fig. 1).
Duration of the first combined antiretroviral regimen 
Six months after the initiation of therapy, 69% were still on 
their first regimen, 54% after 12 months, 48% after 18 months 
and 39% after 24 months. For half of the patients, the duration 
of the initial antiretroviral regimen was equal or shorter than 
14.7 months (441 days) (Fig. 2).
Factors related to the discontinuation of the first antiretroviral 
regimen
Cox proportional hazard model was used to evaluate the 
relative risk of treatment discontinuation. After excluding 
cases with missing values in the demographic variables, 
718 cases were available for the survival analysis. The risk of 
interrupting treatment was not associated with initial CD4, 
marital status, gender, age group or education level.
Irregular dispensing and reports of irregular use of 
medication were evaluated as an indirect measure of patients’ 
non-adherence and in univariate analysis both were risk 
factors (p < 0.001) for HAART discontinuation. Adding the 
variable “regular dispensing” to Cox proportional hazard 
model did not change these results.
Only 318/891 (35.7%) of the patients had a viral load exam 
before starting treatment. Viral load before treatment was 
divided into three categories: up to 9,999; from 10,000 to 
99,999 and higher than 100,000 copies/mL and there was no 
difference in treatment discontinuation in relation to pre-
treatment values.
When the main therapeutic classes were compared, a 
significantly lower discontinuation rate was noticed for 
NNRTI containing regimens at all intervals, as shown in 
Table 1. 
A significant difference (p < 0.001) was observed when 
comparing duration of regimens containing NNRTI to 
those containing PI, when adjusted to baseline CD4+ category 
and to combination of NRTI. In pair-to-pair comparison 
among the eight most frequent regimens, it was noticed that 
Variable Median, n/n (%)
Median age (y) 36.3 
Male 620/891 (69.2%)
White 418/780 (53.5%)
Single 455/873 (52.1%)
Heterosexual male 356/620 (57.4%)
Less than 8 years of education 570/865 (65.8%)
CD4 < 200 cells/mm3 578/859 (66.6%)
AIDS diagnosis 266/859 (31%)
Regimen type  
PI 548 (62.5%)
NNRTI 329 (37.5%)
PI and CD4 < 200 cells/mm3 424/538 (78.8%)
NNTRI and CD4 < 200 cells/mm3 154/329 (46.8%)
Table 1 - Baseline characteristics of 891 patients starting 
antiretroviral therapy from 1996 to 2005
Fig. 1 - Evolution of the percentage of the most frequent 
regimens per year of introduction of HAART. Fig. 2 - Duration of the first antiretroviral regimen in days.
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the combination AZT + 3TC + EFV showed a significantly 
lower discontinuation rate in comparison to other regimens 
(p < 0.05) (Fig. 3).
For 543 participants the first antiretroviral regimen failed 
during the study period. Intolerance/adverse events were the 
main reasons for regimen discontinuation (49.5%), followed 
by virological failure (21.2%) and by abandonment/non-
adherence (21%). In 12 patients the antiretroviral regimen 
was replaced for regimen adequacy, which was not considered 
as discontinuation. In 61 patients the reason for discontinuation 
could not be retrieved from the medical records.
Regarding the drug classes evaluated, a significantly higher 
percentage of patients on NNRTI discontinued their regimens 
due to immunological failure. Discontinuation due to adverse 
events was more common among those using PI-containing 
regimens. Intolerance/adverse events were responsible for the 
discontinuation of 235 regimens. The least tolerated drug was 
ritonavir (RTV) (full dose), which was responsible for 27.6% 
of regimen switches, followed by AZT (18.3%) and didanosine 
(DDI) (17%). Interruption of the initial antiretroviral regimen 
could have been caused by more than one drug. 
In relation to adverse events leading to discontinuation of 
the first antiretroviral regimen, gastrointestinal intolerance 
was responsible for 44.2% of the cases, followed by anemia 
(14.6%) and neuropsychiatric disturbance (6.2%) (Table 2).
advanced immunodeficiency. In 2000, RTV was restricted to use 
as pharmacological adjuvant and PI and NNRTI classes were 
equally indicated for initial therapy. Since 2004, NNRTIs have 
been recommended as first option and PI-containing regimens 
as an alternative for initial therapy. In our sample, a higher 
proportion of PI use by patients with T-CD4+ lymphocyte count 
under 200 cells/mm3 was observed, reflecting the national 
guidelines recommendations at the beginning of the study 
period. Changes in the antiretroviral therapy observed over 
time correspond to modifications in Brazilian guidelines for 
treatment for adults and adolescents infected by HIV.10-17
Late arrival to treatment in this cohort was elevated and 
is probably related to the study period (1995-2005). We do 
not know if that was an exclusive finding for the city of Belo 
Horizonte at that time as there is not much data from other 
Brazilian cities  in that period. Currently, the available data 
for Brazil shows that late arrival comprises approximately 
40% of cases, which is just a bit higher than what is reported 
for the US and western Europe. In Brazil, Souza Jr et al.18 
evaluated 84,964 patients aged 15 or over with an initial T-CD4+ 
lymphocyte count done between 2003 and 2006, and whose 
HAART initiation was subsequent to  the initial CD4+ T cell 
count determination. One third of patients had less than 200 
cells/mm3 and, when combined with number of symptomatic 
individuals, 41% of total group should have received immediate 
antiretroviral drugs (ARV).
In the multivariate analysis, none of the socio-demographic 
variables nor the T-CD4+ lymphocyte count at the beginning 
of HAART turned out to be risk factors for treatment failure 
and/or discontinuation. Although this study was not aimed 
at evaluating the influence of adherence on HAART duration, 
Adverse event Frequency Percentage (%)
Gastrointestinal intolerance 121 44.2
Anemia 40 14.6
Neuropsychiatric disturbances 17 6.2
Drug allergy 15 5.4
Hepatitis 10 3.6
Peripheral neuropathy 7 2.5
Acute pancreatitis 6 2.2
Nephrolithiasis 6 2.2
Dyslipidemia 4 1.5
Lipoatrophy 4 1.5
Hyperlactatemia 3 1.1
Central fat accumulation 3 1.1
Lactic acidosis 3 1.1
No information 35 12.8
TOTAL 274 100
*The two main adverse events described as the reason for regimen 
discontinuation were considered for this analysis. 
Table 2 – Frequency of adverse events* responsible for 
discontinuation of medication
Discussion
Socio-demographic characteristics of the evaluated population 
were similar to the Brazilian reported AIDS cases.9 Since 
1996, HAART is recommended as an option to initial therapy 
in Brazil, when the PIs became available. Until 2001, double 
therapy was the recommended option for patients without 
symptoms or advanced immunodeficiency. In 1998, NNRTI-
class drugs were introduced and the preferential use of PIs was 
recommended for symptomatic patients and/or for those with 
Fig. 3 - Duration of the 8 most frequent antiretroviral 
regimens in treatment-naive patients.
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this variable was indirectly measured. A significant association 
was observed between regular dispensing plus regular use 
of medication and longer duration of the first antiretroviral 
regimen. Although both measurements demonstrated a clear 
association with HAART duration, we noticed that irregular 
dispensing was a more accurate marker of discontinuation in 
the initial regimen, especially in the first months of treatment. 
This difference suggests that some patients may have omitted 
or denied their irregular use of medication to their physician. 
One limitation of this analysis was that it was not possible to be 
sure that patients regularly seeking medication at the pharmacy 
actually made regular use of it, as it has also been seen in 
previous studies carried out in the same outpatient clinic.19,20 
Irregular dispensing of medication remained as a risk factor for 
treatment discontinuation in the multivariate analysis, when 
this variable was added to Cox proportional hazard model. In the 
analysis of reasons for abandonment/non-adherence leading to 
regimen discontinuation, no differences were observed between 
drug classes PI and NNRTI, despite the pill burden and worse 
tolerability to PIs, especially those most often used by patients 
in this study. 
In univariate analysis, pretreatment viral load was not a 
risk factor for treatment discontinuation. This finding is not 
in accordance with some previous reports. As described in the 
literature, high viral load at the beginning of treatment has been 
shown to be a risk factor for treatment discontinuation.21,22 In the 
present study, this analysis may have been compromised by 
the small number of patients (318/891) that had this test available.
When comparing the main therapeutic classes, a lower 
discontinuation rate was observed for the NNRTI class at all 
periods, even after adjusting for T-CD4+ lymphocyte count and 
NRTI backbone at the beginning of treatment. In the pair-to-
pair comparison amongst the eight most frequent regimens, 
combination AZT + 3TC + EFV showed a significantly lower 
discontinuation rate than the other regimens (p < 0.05). Three 
major randomized clinical studies initiated between 1997 
and 1999 to evaluate the safety and effectiveness of regimens 
containg either a PI or an NNRTI showed similar increases in 
T-CD4+ lymphocyte count, and higher viral suppression in the 
group using NNRTI.23-25 In a metanalysis of 53 clinical trials 
performed from 1994 to 2004 and involving 14,264 patients, 
Bartlett et al.26 observed a significantly higher percentage of 
viral load below 50 copies/mL in week 48 among patients on 
regimens containing either a PI/r (ritonavir-boosted protease 
inhibitors) or in those containing a NNRTI when compared to 
regimens containing a PI without booster.
Intolerance/adverse events were the main reason for 
discontinuation of the initial regimen. The least tolerated drug 
was RTV alone, which was responsible for 27.6% of the regimen 
switches due to intolerance, followed by AZT (18.3%) and DDI 
(17%). Gastrointestinal intolerance to RTV is well documented 
and in the studied population it was the only protease inhibitor 
in 150 patients. Currently, RTV is only recommended in small 
doses, as a pharmacological adjuvant, as even at full dose is 
less efficacious and is associated with a high frequency of 
adverse events.22,27 Myelosuppression related to AZT, leading 
especially to anemia and neutropenia, is a well described 
adverse event.26 It is possible that the large percentage of 
patients with advanced immunosuppression and symptoms 
at the beginning of HAART might have contributed to the 
lower tolerance to AZT. As previously reported, several adverse 
events are common to all antiretroviral classes, limiting future 
options of antiretroviral regimens.27-29
As for duration and reasons for discontinuation of initial 
HAART, some observational studies corroborate the results 
here obtained. O’Brien et al.22, in a retrospective cohort of 345 
patients, observed after an average follow-up of 8.1 months 
that 61% of the patients interrupted initial HAART, with a 
cumulative probability of 51% of interrupting treatment after 
one-year of follow-up. Adverse events were the main reason for 
treatment discontinuation (24%), the most common of which 
being gastrointestinal intolerance. Therapeutic failure was the 
reason for treatment discontinuation in 12% of patients. 
The study regimens of the above-mentioned study corresponded 
to 43.5% of the prescriptions of the present study, in which a 
similar average duration was observed after one year follow-up 
(54%). In the current study we found similar results, with a 
higher proportion of therapeutic failure, probably due to the 
longer follow-up period. In another Brazilian observational study 
with 498 patients, Brito et al.30 reported that 36% interrupted 
initial HAART within the first six months of treatment. They 
did not observe either the association of T-CD4+ lymphocyte 
count or the type of antiretroviral treatment with regimen 
discontinuation. There was a significant association with low 
education level and age between 25 and 34 years, which was not 
observed in this study.
Regarding differences in the initial therapy duration 
between the PI- and NNRTI-containing regimens, Dorucci et 
al.21 evaluated the use of combined therapy as first regimen, 
initiated between 1997 and 2000, to compare the discontinuation 
rates among patients on PI versus NNRTI. Average follow-up 
time was 9.7 months (11 months for patients on PI and 5.6 
months for those on NNRTI). The majority was receiving a 
PI-containing regimen (85.4%). Eight hundred and fifty-seven 
patients interrupted the first antiretroviral regimen, 777 (45.5%) 
of then were on PI and 80 (27.3%) on NNRTI. Toxicity was the 
reason for discontinuation for 42.7%, followed by therapeutic 
failure (28.5%) and non-adherence (23%). These results are 
similar to the current study, although the cumulative probability 
of interrupting treatment after one year was lower (37.5%) 
and there was no significant difference between drug classes 
regarding time for discontinuation considering all reasons. 
In relation to therapeutic failure, Dorucci et al.21 reported a 
tendency for less discontinuation of the NNRTI group, differently 
from what was observed in this study. Other published data 
have indicated that overall discontinuation or modification of 
HAART regimens ranges from 8% to 59% (median 33%).26
The high frequency of regimens known to be less tolerated or 
less effective at the beginning of the period evaluated may have 
had an influence on the worse performance of PI-containing 
regimens. Current literature demonstrates the superiority 
of NNRTI-containing regimens when compared to PI-based 
regimens without a pharmacological booster. Therefore, the 
results of the current study were as expected. RTV boosted 
PI-containing regimens (IP/r), however, have shown an efficacy 
similar to those containing an NNRTI, with a lower chance 
of virological failure, but with higher frequency of adverse 
events.26,31-33 However, RTV-boosted regimens correspond 
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to only 9.6% of the regimens herein evaluated, most of them 
with saquinavir/R (SQV/R) and indinavir/R (IDV/R), following 
the recommendations at that period. Also, the numbers 
were too small to analyze such regimens separately. On the 
other hand, this study provides important information about 
NNRTIs, especially EFV, and corroborates its use as drug of 
choice to compose the initial regimen in the current Brazilian 
recommendations. Furthermore, the long observation period 
and the large number of patients evaluated, combined with 
the similarity of the population studied with the Brazilian 
reported AIDS cases provide useful information for choosing 
the initial regimen in the country. Observational studies such 
as this complement the results obtained in clinical trials, as 
the former include patients with several socio-demographic 
characteristics in real life situaions.34
Medical records with incomplete information were a 
limitation in this study. Variables not found were considered as 
missing answers, which limited the analysis of some important 
variables, such as viral load. As only 96 patients had virological 
failure as the reason for discontinuation, this analysis was not 
performed. We do believe that if this evaluation would be done 
now, in a situation where there is ample access to viral load 
determination we would probably find more virological failure 
and drug substitution would have occurred sooner.
Conclusion
This study presents relevant information about several aspects 
of the first highly active antiretroviral regimen in Brazil. Even 
with free access to antiretroviral medication, for 61% of the 
patients there was failure or discontinuation of the regimen in 
the first 24 months of treatment. Nonetheless, these results are 
similar to those reported in industrialized countries.2,35 NNRTI-
containing regimens, especially with EFV, were more durable 
and effective than those of PI-containing regimens. Irregular 
dispensing of medication was a risk factor for treatment 
failure and/or discontinuation. Although more powerful and 
better tolerated antiretroviral drugs have been developed, 
poor adherence and the high rate of adverse events remain as 
the main obstacles for a long-term success of the treatment. 
Furthermore, it must be emphasized that a substantial 
percentage of patients initiated therapy with advanced 
symptoms and/or immunosuppression, which reduces the 
chances of therapeutic success and increases mortality in 
the assisted population. 
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